Collectively, these findings suggest that while changes in serum protein markers have limited predictive capabilities, cfDNA-based AFP quantification offers superior accuracy for monitoring treatment response, and AFP+ CTC detection provides high specificity for identifying non-responders, supporting their complementary roles in improving response assessment in HCC. The gene discussed is AFP; the disease is hepatocellular carcinoma.